| CERTIFICATE OF DETERMINATION OF MEMBER | |
Citation: | French v Harwood Slipway Pty Ltd & others [2022] NSWPIC 473 |
| APPLICANT: | Riley Terrence French |
| RESPONDENT: | Harwood Slipway Pty Limited |
| Member: | Gaius Whiffin |
| DATE OF DECISION: | 25 August 2022 |
| CATCHWORDS: | WORKERS COMPENSATION - Claims for injuries to back and legs; claim for treatment expenses pursuant to section 60 of the Workers Compensation Act 1987 (1987 Act); medicinal cannabis; consideration of applicant’s statements, medical reports and other treatment records, claim correspondence, and factual material; consideration of whether the prescription of medicinal cannabis is reasonably necessary medical treatment as a result of the injury to the applicant’s back on 20 July 2009 which arose out of or in the course of his employment with the respondent; Honarvar v Professional Painting AU Pty Limited, Rose v Health Commission, Diab v NRMA Limited and Murphy v Allity Management Services Pty Limited considered; Held — the prescription of medicinal cannabis is recently necessary medical treatment so long as approval is obtained from the Therapeutic Goods Administration as a result of the applicant’s back injury; the evidence only allows the Commission to order payment for the costs of and incidental to the applicant being prescribed with medicinal cannabis into the future for a period of 73 days; award that the respondent pay the applicant’s past section 60 of the 1987 Act expenses in relation to the prescription of medicinal cannabis; award that the respondent pay the applicant’s future section 60 of the 1987 Act expenses for 73 days in relation to the prescription of medicinal cannabis; no orders or findings made regarding the applicant’s future section 60 of the 1987 Act expenses in relation to the prescription of medicinal cannabis beyond the period of 73 days. |
| determinations made: | The Commission determines: 1. The prescription of medicinal cannabis (Arizer Solo II Vapouriser Inhalation Device, Beacon Medical THC+F Flower 20% THC Sensi Star Indica Dried Herb, LGP Classic 20:5 Oil, and MGC MP 1:1 Oil) to the applicant as referred to in the reports from Dr Adams dated 19 October 2020 and 5 January 2021, is reasonably necessary medical treatment (so long as approval is obtained from the Therapeutic Goods Administration) as a result of the applicant’s back injury, which arose out of or in the course of his employment with the respondent on 20 July 2019. 2. The Commission only has evidence before it to allow it to order payment for the costs of and incidental to the applicant being prescribed with medicinal cannabis (as described above) into the future for a period of 73 days – if the applicant requires this prescription for a longer period, he will need to make an appropriate claim upon the respondent in this regard – the Commission currently makes no determination regarding the applicant’s entitlements following the relevant period of 73 days. The Commission orders: 1. The respondent is to pay to the applicant an amount of $1,770 (with credit to be given to the respondent for any amounts already paid),… |
Keep reading for free
Create a free CaseChat account to read French v Harwood Slipway Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2022] NSWPIC 473
- Decision Date
CaseChat Overview and Summary
The legal issues central to the case revolved around whether the prescription of medicinal cannabis constituted reasonably necessary medical treatment for the applicant's back injury. This determination required the court to examine the applicant's statements, medical reports, and treatment records, along with the factual material and correspondence pertaining to the claim. The court was also required to consider relevant precedents such as Honarvar v Professional Painting AU Pty Limited, Rose v Health Commission, Diab v NRMA Limited, and Murphy v Allity Management Services Pty Limited.
The court found that the prescription of medicinal cannabis was reasonably necessary medical treatment if approval from the Therapeutic Goods Administration was obtained. The evidence presented allowed the Commission to order the payment of costs related to the applicant's prescription of medicinal cannabis for a period of 73 days into the future. The court ruled that the respondent should pay the applicant's past expenses for medicinal cannabis under section 60 of the 1987 Act. Additionally, the respondent was ordered to pay the applicant's future expenses for medicinal cannabis for 73 days. No orders or findings were made concerning the applicant's future expenses beyond this 73-day period.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.